The Firm is representing funds advised by Apax Partners in connection with the announced acquisition of all outstanding shares of rue21, Inc. (Nasdaq: RUE) for approximately $1.1 billion, including the assumption of debt. Approximately 30% of the outstanding shares of rue21 are collectively owned by SKM II funds. The transaction is expected to close before the end of the year and is subject to approval by the majority of the stockholders unaffiliated with the SKM II funds as well as customary closing conditions.

More >>

Xellia Pharmaceuticals, a pharmaceutical group focusing on the development, manufacturing and global commercialization of anti-infective therapies, announced that Novo A/S, the holding company of the Novo Group, has entered into an agreement to purchase all shares of the group for approximately US $700 million from 3i and other current shareholders, as detailed in the company press release below. Closing of the transaction will be subject to relevant competition law approvals, and is expected to take place during the third quarter of 2013.

More >>

Cahill represented Morgan Stanley as administrative agent and Morgan Stanley and Jefferies as arrangers in connection with the $240,000,000 Term B Loan for Alvogen Pharma US, Inc. Proceeds from the loan will be used for general corporate purposes and to refinance existing indebtedness.

More >>

The Firm represented the underwriters, led by Citigroup Global Markets Inc., Goldman, Sachs & Co., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, in connection with a registered offering by Kimberly-Clark Corporation (“Kimberly-Clark”) of notes in $850 million aggregate principal amount.

More >>

Simpson Thacher represented the underwriters, led by J.P. Morgan Securities LLC, in an offering of $550 million in aggregate principal amount of 2.375% Senior Notes due 2018 and $550 million in aggregate principal amount of 3.750% Senior Notes due 2023 by Total System Services, Inc. (“TSS”).

More >>